Author: jauca

31 Mar [51] New Drugs VIII – Telithromycin (Ketek®), Ezetimibe (Ezetrol®), Topical Pimecrolimus (Elidel®), and Tacrolimus (Protopic®)

Posted at 00:00h in Therapeutics Letter 0 Comments

Share

Telithromycin (Ketek®) Ezetimibe (Ezetrol®) Topical Pimecrolimus (Elidel®) and Tacrolimus (Protopic®) References Telithromycin (Ketek®) Approved indications: Community-acquired pneumonia (mild to moderate) (CAP), acute bacterial exacerbation of chronic bronchitis (AECB), and tonsillitis/pharyngitis (patients intolerant to beta-lactam antibiotics). Mechanism of action:  Telithromycin is...

Read More

31 Dec [50] Can blood pressure be lowered by a change in diet? Evidence from the DASH trials

Posted at 00:00h in Therapeutics Letter 1 Comment

Share

Case You have been following a 52-year-old Caucasian nurse with menopausal symptoms for the last 2 years. You have not prescribed anything and her symptoms are dissipating. You have recorded 6 sets of blood pressure (BP)...

Read More

30 Nov What Effects do Provincial Drug Plan Coverage Policies for New Drugs have on Patterns of Use and Cost.

Posted at 00:15h in PharmacoEpidemiology 0 Comments

Share

Read More

30 Sep [49] Statin’s benefit for secondary prevention confirmed. What is the optimal dosing strategy?

Posted at 00:00h in Therapeutics Letter 0 Comments

Share

Introduction Letters #24, 27 and 42 recommended statin therapy for patients with ischemic heart disease (secondary prevention) based on 3 relevant randomized controlled trials (RCTs): 4S1, CARE2, and LIPID3. Letter #48 pooled the data from the...

Read More